CYCLOPHARM LIMITED — Capital/Financing Update 2026

Apr 19, 2026

20 April 2026

cyclo pharm

cyclo medica techne gas

==> picture [41 x 52] intentionally omitted <==

Cyclopharm Ltd ABN 74 116 931 250 Unit 4, 1 The Crescent Kingsgrove NSW 2208 Australia T 61 2 9541 0411 F 61 2 9543 0960 www.cyclopharm.com.au

NOTICE UNDER SECTION 708A(5) OF THE CORPORATIONS ACT 2001 (CTH)

On 4 February 2026, Cyclopharm Limited (the “ Company ”) announced a placement (“ Placement” ) of 14,736,842 new fully paid ordinary shares at $0.95 per share raising A$14 million before costs.

The Company completed a share placement to institutional investors of 9,473,684 new fully paid ordinary shares (“ T1 Placement Shares ”) (representing A$9 million before costs). The T1 Placement Shares were issued on 11 February 2026.

The remaining 5,263,158 shares ( “T2 Placement Shares” ) (representing A$5 milllion) have been issued today.

Accordingly, the Company advises:

• 1 The T2 Placement Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act 2001 (Cth) (the “ Act ”).

• 2 This notice is being given under section 708A(5)(e) of the Act.

• 3 As at the date of this notice, the Company has complied with:

• (a) the provisions of Chapter 2M of the Act as they apply to the Company; and

• (b) sections 674 and 674A of the Act.

• 4 As at the date of this notice, there is no excluded information as defined in sections 708A(7) and 708A(8) of the Act which is required to be disclosed by the Company.

This ASX announcement was approved and authorised for release by James McBrayer, Managing Director, CEO and Company Secretary.

For more information, please contact:

Mr James McBrayer Managing Director, CEO and Company Secretary Cyclopharm Limited T: +61 (02) 9541 0411

Page 1 of 1